New vaccine trial in Tuberculosis
- By:groshan fabiola
The trials will take place in the US. And will be conducted by biotechnology company Corixa and GlaxoSmithKline Biologicals, along with the National Institutes of Health. The new vaccine is made with several proteins from the bacterium that causes tuberculosis (TB), it is the first recombinant tuberculosis vaccine. Specialist have great hopes in reducing the burden of a disease that claims so many lives every year with the help of this vaccine.
Two proteins were discovered in the blood of some people with a long term infection who never became ill, those proteins are supposed to stimulate strong immune responses. The scientist refined adjuvant technologies and developed better methods of vaccine delivery.
The vaccine has to prove safe in its initial testing stage, to be further tested. BCG offers some protection against TBC but, in young children and is not very effective against pulmonary TB which is the most contagious form of disease. Millennium Vaccine Initiative is enabling the scientists to refine adjuvant technologies and to develop better methods of vaccine delivery.
Versions of the candidate vaccine were already tested in animals through a contract facility, at Colorado State University. According to some studies tuberculosis will still affect a high percent of the earth for some time, is the leading cause of Disability Adjusted Life Years.
BCG (live attenuated Mycobacterium bovis BCG) is the only vaccine currently available against tuberculosis, it is administered in the Expanded Programme for Immunization. It has been proved to protect against disseminated and meningeal TB in young children, and to provide some protection against leprosy. In studies conducted throughout the world its efficacity has varied dramatically. BCG consists of the virulent M.Bovis attenuated. Today, there are a variety of related "BCG" vaccines that today have varying genotypic and phenotypic characteristics, distributed strains have been propagated throughout the world under varying conditions. The various exposure to environmental mycobacteria may be the single contributor to the variability in BCG’s efficacy.
Studies are being conducted to observe exactly how the BCG’s efficacy in different trials can be attributed to genetic differences. BCG’efficacy is limited in immunocompromised individuals and may be interferating with tuberculin skin test screening. The new vaccine has been produced by using the recombinant DNA technology and is hoped to be a great discovery and to increase the chances of survival and curing of tuberculosis. Annual deaths from tuberculosis are still ten times greater than all the deaths from HIV put together.
For the same reasons that tuberculosis has always flourished unemployment, overcrowding, misery and migration. The recidivation of tuberculosis has been observed in those people and sometimes no reaction to the antitubeculous therapy or at least not the expected reaction.About the author:
So, if you want to find more about tuberculosis treatments or even about mycobacterium tuberculosis please click this link http://www.tuberculosis-center.com